SCHEMBL607213

SCHEMBL607213

OC(CN1CCN(Cc2ccc3c(c2)OCO3)CC1)Cn1c2ccc(Br)cc2c2cc(Br)ccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAX Q07812 1/20 0.57
MAPT P10636 3/20 0.56
ALOX15 P16050 3/20 0.56
TP53 P04637 1/20 0.56
CYP3A4 P08684 1/20 0.56
MAPK1 P28482 1/20 0.56
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
RAD52 P43351 1/20 0.54
KDM4E B2RXH2 3/20 0.54
LMNA P02545 5/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
HTT P42858 3/20 0.51
GAA P10253 3/20 0.50
ALDH1A1 P00352 2/20 0.50
MCHR1 Q99705 1/20 0.50
USP2 O75604 1/20 0.50
RAB9A P51151 1/20 0.50
TSHR P16473 1/20 0.49
ALOX12 P18054 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL609438 0.95 MEN1 (0.63) BAXMAPTALOX15TP53CYP3A4
SCHEMBL7648643 0.92 BAX (0.49) BAXMAPTALOX15TP53CYP3A4
SCHEMBL608259 0.89 MEN1 (0.63) BAXMAPTALOX15TP53CYP3A4
SCHEMBL1304932 0.86 LMNA (0.67) MAPTALOX15MAPK1MEN1KMT2A
SCHEMBL1306296 0.83 LMNA (0.60) MAPTTP53MAPK1MEN1KMT2A
SCHEMBL610337 0.83 MEN1 (0.66) BAXMAPTALOX15TP53CYP3A4
SCHEMBL607747 0.82 BAX (0.61) BAXMAPTALOX15TP53CYP3A4
SCHEMBL6819686 0.82 BAX (0.82) BAXMAPTALOX15TP53CYP3A4
SCHEMBL5022852 0.81 BAX (0.63) BAXMAPTALOX15TP53CYP3A4
SCHEMBL605834 0.81 BAX (0.63) BAXMAPTALOX15TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP claimed
US-8410110-B2 9-(piperazinylalkyl) carbazoles as Bax-modulators MERCK SERONO SA (CH) 2013-04-02 US disclosed
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2012-02-16 US disclosed
US-8053436-B1 9-(piperazinylalkyl) carbazoles as bax-modulators MERCK SERONO SA (CH) 2011-11-08 US disclosed
EP-1237887-B1 9-(PIPERAZINYLALKYL)CARBAZOLES AS BAX-MODULATORS SERONO LAB (CH) 2008-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040933-A1 9-(PIPERAZINYLALKYL) CARBAZOLES AS BAX-MODULATORS BCL2, BAX, BAD BAX 2/4885MAPT 1085/4885ALOX15 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.